-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$29.001212.22% Upside
Recent Analyst Forecasts and Stock Ratings
Allogene Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Allogene Therapeutics, Inc.?
Allogene Therapeutics, Inc. has been rated by research analysts at H.C. Wainwright, B.Riley Financial, Robert W. Baird, Guggenheim, Canaccord Genuity, Roth Capital in the past 90 days.